1 However there are very few studies to evaluate other functions of atorvastatin except for blood lipid concentration reduction and the effect of different doses of atorvastatin usage that related to oxidative stress and cardiac function among ischemic Cardiomyopathy
A review of the Ischemic Cardiomyopathy
products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Comparison of benefits from cardiac resynchronization therapy in patients with ischemic cardiomyopathy
versus idiopathic dilated cardiomyopathy.
The Phase 1/2 POSEIDON study enrolled 31 patients with chronic ischemic left ventricular (LV) dysfunction due to ischemic cardiomyopathy
BioVentrix has shown in multiple clinical trials in Europe that the exclusion of scar tissue from the LV cavity in patients suffering from ischemic cardiomyopathy
and heart failure symptoms results in substantial improvements in LV volume, NYHA Class, 6 minute walk tests, and Quality of Life.
Past trials with ixmyelocel-T have shown better results in patients with ischemic cardiomyopathy
than in those with nonischemic cardiomyopathy, a form of heart disease that is caused by heart muscle disorders, so the new trial enrolled only patients with ischemic cardiomyopathy
A standardized definition of ischemic cardiomyopathy
for use in clinical research.
Type Subtypes Cardiomyopathies Hypertrophic cardiomyopathy Dilated cardiomyopathy Restrictive cardiomyopathy Arrhythmogenic right-ventricular cardiomyopathy Unclassified Specific Ischemic cardiomyopathy
cardiomyopathies Valvular cardiomyopathy Hypertensive cardiomyopathy Inflammatory cardiomyopathy Myocarditis Idiopathic Infective Autoimmune Metabolic cardiomyopathy Endocrine Familial storage disease and infiltrations Deficiency Amyloidosis General system disease Connective tissue disorders Infiltrations and granulomas Muscular dystrophies Neuromuscular disorders Sensitivity and toxic reactions Peripartal cardiomyopathy Table 2.
MIs cause fatal dysrhythmias, ischemic cardiomyopathy
MIs cause fatal dysrhythrnias, ischemic cardiomyopathy
GlobalData's clinical trial report, Ischemic Cardiomyopathy
Global Clinical Trials Review, H1, 2012" provides data on the Ischemic Cardiomyopathy
clinical trial scenario.
BioVentrix has shown that the exclusion of scar tissue from the LV cavity in patients suffering from ischemic cardiomyopathy
heart failure results in substantial improvements in Quality of Life.